Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) — Stock Price
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) is currently trading at $2.24 USD, up 2.28% today. Over the past 52 weeks, shares have ranged between $1.85 and $3.97. This page tracks Lakewood-Amedex Biotherapeutics Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Lakewood-Amedex Biotherapeutics Inc. Com market capitalisation.
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Lakewood-Amedex Biotherapeutics Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Lakewood-Amedex Biotherapeutics Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research & Development | $1.26 Million | $2.10 Million | $5.53 Million |
| SG&A | $2.51 Million | $1.92 Million | $3.10 Million |
| Total Operating Expenses | $3.77 Million | $4.03 Million | $8.64 Million |
| Operating Income | $-3.77 Million | $-4.03 Million | $-8.64 Million |
| EBITDA | — | — | — |
| EBIT | — | — | — |
| Interest Expense | $100.88K | $5.00K | $10.00K |
| Income Before Tax | $-3.85 Million | $-4.86 Million | $-8.28 Million |
| Income Tax Expense | — | — | — |
| Net Income | $-3.85 Million | $-4.86 Million | $-8.28 Million |
Lakewood-Amedex Biotherapeutics Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Lakewood-Amedex Biotherapeutics Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Assets | $481.60K | $1.07 Million | $6.89 Million |
| Total Current Assets | $305.39K | $773.98K | $6.48 Million |
| Cash & Equivalents | — | — | — |
| Short-term Investments | — | $0.00 | $3.86 Million |
| Net Receivables | — | — | — |
| Inventory | — | — | — |
| Property, Plant & Equipment | — | — | — |
| Goodwill | — | — | — |
| Total Liabilities | $2.45 Million | $660.97K | $2.34 Million |
| Total Current Liabilities | $2.41 Million | $500.63K | $2.06 Million |
| Long-term Debt | — | — | — |
| Net Debt | $1.26 Million | — | — |
| Total Stockholder Equity | $-1.96 Million | $409.61K | $4.56 Million |
| Retained Earnings | $-53.35 Million | $-49.50 Million | $-44.65 Million |
Lakewood-Amedex Biotherapeutics Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Lakewood-Amedex Biotherapeutics Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Cash Flow | $-1.94 Million | $-5.72 Million | $-6.82 Million |
| Capital Expenditures | $0.00 | $1.85K | $0.00 |
| Free Cash Flow | $-1.94 Million | $-5.73 Million | $-6.82 Million |
| Investing Cash Flow | — | — | — |
| Financing Cash Flow | $1.50 Million | $-50.00K | $0.00 |
| Dividends Paid | — | — | — |
| Stock-Based Compensation | $1.35 Million | $269.67K | $608.24K |
| Depreciation | $119.98K | $118.59K | $120.98K |
| Change in Cash | $-444.70K | $-1.85 Million | $-10.60 Million |
Lakewood-Amedex Biotherapeutics Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Lakewood-Amedex Biotherapeutics Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 28, 2026 | — | 0.65 | — |